124 related articles for article (PubMed ID: 1093059)
1. Chemotherapy of prostatic cancer.
Schmidt JD
Urol Clin North Am; 1975 Feb; 2(1):185-96. PubMed ID: 1093059
[TBL] [Abstract][Full Text] [Related]
2. [Predictive value of clinical, biochemical, hormonal and histologic parameters of the endocrine response in prostatic adenocarcinoma].
Burgos FJ; Maganto E; Jiménez M; Mayayo T; Allona A; Mateos A; Escudero A; Romero-Aguirre C
Actas Urol Esp; 1988; 12(6):500-6. PubMed ID: 3232555
[No Abstract] [Full Text] [Related]
3. The EORTC Phase III trials in prostatic cancer.
Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
[No Abstract] [Full Text] [Related]
4. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
Kalland T; Haukaas S
Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
[TBL] [Abstract][Full Text] [Related]
5. Estracyt--clinical experiences.
Nilsson T
Scand J Urol Nephrol Suppl; 1980; 55():135-8. PubMed ID: 6938016
[TBL] [Abstract][Full Text] [Related]
6. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
Benson RC; Cummings K
Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
[No Abstract] [Full Text] [Related]
7. [Serum testosterone and acid phosphatase levels in patients with prostatic cancer treated with Estracyt].
Németh A; Morvay J; Vécsei B
Orv Hetil; 1981 Apr; 122(17):1017-20. PubMed ID: 7022313
[No Abstract] [Full Text] [Related]
8. [Advanced prostatic cancer: therapeutic modalities].
Faul P; Altwein JE
Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1975-80. PubMed ID: 6391887
[No Abstract] [Full Text] [Related]
9. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents.
Akaza H; Isurugi K; Oishi Y; Kitajima K; Sawamura Y; Baba S; Yoshida K; Otani M; Harada M; Gunji A
Jpn J Clin Oncol; 1988 Dec; 18(4):343-55. PubMed ID: 2462651
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of advanced prostatic cancer today.
Murphy GP; Merrin CE
Prog Clin Biol Res; 1976; 6():285-99. PubMed ID: 139614
[No Abstract] [Full Text] [Related]
12. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
Nickel CJ; Morales A
Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy of hormone-unresponsive prostatic cancer and its metastatic foci].
Kotake T
Gan To Kagaku Ryoho; 1982 Mar; 9(3):387-96. PubMed ID: 6764105
[TBL] [Abstract][Full Text] [Related]
14. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
Hauchecorne J
Prog Clin Biol Res; 1987; 243B():229-34. PubMed ID: 3309983
[No Abstract] [Full Text] [Related]
15. Chemotherapy of hormonally unresponsive prostatic carcinoma.
deKernion JB; Lindner A
Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779
[TBL] [Abstract][Full Text] [Related]
16. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
[No Abstract] [Full Text] [Related]
17. [Chemotherapy of prostatic cancer].
Portnoĭ AS
Vopr Onkol; 1985; 31(9):3-12. PubMed ID: 2931901
[No Abstract] [Full Text] [Related]
18. [Stage D1 prostatic cancer benefited by a single regimen of Estracyt].
Hata M
Gan To Kagaku Ryoho; 1988 May; 15(5):1787-90. PubMed ID: 3369873
[TBL] [Abstract][Full Text] [Related]
19. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
De la Grange AB
Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
[No Abstract] [Full Text] [Related]
20. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
